Performance/ Research Phase
IGF-1 DES (1-3)
Subcutaneous injection (weekly), Oral (daily - Rybelsus)
Overview
IGF-1 DES (1-3) is a truncated analogue of insulin-like growth factor 1 lacking the first three N-terminal amino acids (glycine-proline-glutamate). This structural modification prevents binding to IGF binding proteins in serum, resulting in a shorter half-life but significantly increased potency at the IGF-1 receptor compared to native IGF-1.
Mechanism of Action
The peptide is hypothesized to promote localized muscle hypertrophy and tissue repair through enhanced receptor activation in target tissues.
​Research Summary & Key Findings
No controlled clinical trials have been published in peer-reviewed journals. Evidence is limited to preclinical cell culture and animal models demonstrating increased myoblast proliferation and differentiation. This agent remains unregulated and its safety and efficacy in humans have not been established through formal investigation.
Clinical Status
Research Phase
IGF-1 DES (1-3) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
Subcutaneous injection (weekly)
Oral (daily - Rybelsus)
References
PRIMARY LITERATURE
PRIMARY LITERATUREPeer-reviewed literature indexed by the National Library of Medicine.
Registered interventional and observational studies, including status and phase.
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.